Hosted on MSN3m
EC authorises Celltrion’s Avtozma for multiple indicationsIn August 2024, the EC approved the company’s SteQeyma (CT-P43), a Stelara (ustekinumab) biosimilar for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback